Published in Neuropsychopharmacology on July 27, 2011
Power failure: why small sample size undermines the reliability of neuroscience. Nat Rev Neurosci (2013) 13.37
The vascular depression hypothesis: mechanisms linking vascular disease with depression. Mol Psychiatry (2013) 2.17
So depression is an inflammatory disease, but where does the inflammation come from? BMC Med (2013) 2.02
Sex Differences in the Peripheral Immune System in Patients with Depression. Front Psychiatry (2017) 1.90
Understanding the somatic consequences of depression: biological mechanisms and the role of depression symptom profile. BMC Med (2013) 1.78
The inflammasome: pathways linking psychological stress, depression, and systemic illnesses. Brain Behav Immun (2012) 1.42
Depression and sickness behavior are Janus-faced responses to shared inflammatory pathways. BMC Med (2012) 1.37
Candidate genes expression profile associated with antidepressants response in the GENDEP study: differentiating between baseline 'predictors' and longitudinal 'targets'. Neuropsychopharmacology (2012) 1.28
Inflammasomes in neuroinflammation and changes in brain function: a focused review. Front Neurosci (2014) 1.26
Dynamic microglial alterations underlie stress-induced depressive-like behavior and suppressed neurogenesis. Mol Psychiatry (2013) 1.26
A dialogue between the immune system and brain, spoken in the language of serotonin. ACS Chem Neurosci (2012) 1.20
Dysregulated relationship of inflammation and oxidative stress in major depression. Brain Behav Immun (2012) 1.18
Pro-inflammatory cytokines as predictors of antidepressant effects of exercise in major depressive disorder. Mol Psychiatry (2012) 1.17
Cumulative meta-analysis of interleukins 6 and 1β, tumour necrosis factor α and C-reactive protein in patients with major depressive disorder. Brain Behav Immun (2015) 1.10
New drug targets in depression: inflammatory, cell-mediated immune, oxidative and nitrosative stress, mitochondrial, antioxidant, and neuroprogressive pathways. And new drug candidates--Nrf2 activators and GSK-3 inhibitors. Inflammopharmacology (2012) 1.06
Evidence for sustained elevation of IL-6 in the CNS as a key contributor of depressive-like phenotypes. Transl Psychiatry (2012) 1.06
Long-term inflammation increases risk of common mental disorder: a cohort study. Mol Psychiatry (2013) 1.01
Inflammation, obesity, and metabolic syndrome in depression: analysis of the 2009-2010 National Health and Nutrition Examination Survey (NHANES). J Clin Psychiatry (2014) 0.99
Treating depression and depression-like behavior with physical activity: an immune perspective. Front Psychiatry (2013) 0.95
Increased risk of depression in patients with rheumatoid arthritis: a seven-year population-based cohort study. Clinics (Sao Paulo) (2015) 0.94
Impact of antidepressants on cytokine production of depressed patients in vitro. Toxins (Basel) (2013) 0.94
Neuroinflammation and comorbidity of pain and depression. Pharmacol Rev (2013) 0.93
The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [¹¹C]PBR28 PET study. Brain Behav Immun (2013) 0.92
Interplay between pro-inflammatory cytokines and growth factors in depressive illnesses. Front Cell Neurosci (2013) 0.92
Depression and cardiovascular disease: an update on how course of illness may influence risk. Curr Psychiatry Rep (2014) 0.91
Reduction of kynurenic acid to quinolinic acid ratio in both the depressed and remitted phases of major depressive disorder. Brain Behav Immun (2015) 0.91
Vagus Nerve Stimulation. Curr Behav Neurosci Rep (2014) 0.90
Interleukin-6 gene (IL-6): a possible role in brain morphology in the healthy adult brain. J Neuroinflammation (2012) 0.89
Systematic review of proinflammatory cytokines in obsessive-compulsive disorder. Curr Psychiatry Rep (2012) 0.88
Optimizing the Exercise Prescription for Depression: The Search for Biomarkers of Response. Curr Opin Psychol (2015) 0.88
Markers of inflammation in schizophrenia: association vs. causation. World Psychiatry (2014) 0.86
Role of neuro-immunological factors in the pathophysiology of mood disorders. Psychopharmacology (Berl) (2016) 0.86
Effect of selective serotonin reuptake inhibitors and immunomodulator on cytokines levels: an alternative therapy for patients with major depressive disorder. Clin Dev Immunol (2013) 0.85
NLRP3 Inflammasome Mediates Chronic Mild Stress-Induced Depression in Mice via Neuroinflammation. Int J Neuropsychopharmacol (2015) 0.85
Dysregulation of leukocyte gene expression in women with medication-refractory depression versus healthy non-depressed controls. BMC Psychiatry (2013) 0.84
Peripheral and Central Mechanisms of Stress Resilience. Neurobiol Stress (2015) 0.84
Ketamine exerts antidepressant effects and reduces IL-1β and IL-6 levels in rat prefrontal cortex and hippocampus. Exp Ther Med (2013) 0.84
Plasma Levels of IL-23 and IL-17 before and after Antidepressant Treatment in Patients with Major Depressive Disorder. Psychiatry Investig (2013) 0.84
Effects of psychotropic drugs on inflammation: consequence or mediator of therapeutic effects in psychiatric treatment? Psychopharmacology (Berl) (2015) 0.84
Psychoneuroimmunology of Early-Life Stress: The Hidden Wounds of Childhood Trauma? Neuropsychopharmacology (2016) 0.83
Inflammatory and metabolic dysregulation and the 2-year course of depressive disorders in antidepressant users. Neuropsychopharmacology (2014) 0.83
Cytokine variations and mood disorders: influence of social stressors and social support. Front Neurosci (2014) 0.83
Integrating Interleukin-6 into depression diagnosis and treatment. Neurobiol Stress (2016) 0.83
Mind and body: how the health of the body impacts on neuropsychiatry. Front Pharmacol (2013) 0.82
Elevated level of DNA damage and impaired repair of oxidative DNA damage in patients with recurrent depressive disorder. Med Sci Monit (2015) 0.82
Pathogenetic and Therapeutic Applications of Tumor Necrosis Factor-α (TNF-α) in Major Depressive Disorder: A Systematic Review. Int J Mol Sci (2016) 0.81
Antidepressant-like effect of celecoxib piroxicam in rat models of depression. J Neural Transm (Vienna) (2014) 0.81
Controversies about a common etiology for eating and mood disorders. Front Psychol (2014) 0.81
Antidepressant therapy in epilepsy: can treating the comorbidities affect the underlying disorder? Br J Pharmacol (2013) 0.81
Soyo-san reduces depressive-like behavior and proinflammatory cytokines in ovariectomized female rats. BMC Complement Altern Med (2014) 0.81
Depression and frailty in later life: a systematic review. Clin Interv Aging (2015) 0.80
A depressive phenotype induced by Bacille Calmette Guérin in 'susceptible' animals: sensitivity to antidepressants. Psychopharmacology (Berl) (2012) 0.80
N-3 (omega-3) polyunsaturated Fatty acids in the pathophysiology and treatment of depression: pre-clinical evidence. CNS Neurol Disord Drug Targets (2013) 0.80
Altered inflammatory activity associated with reduced hippocampal volume and more severe posttraumatic stress symptoms in Gulf War veterans. Psychoneuroendocrinology (2014) 0.80
The Involvement of TNF-α in Cognitive Dysfunction Associated with Major Depressive Disorder: An Opportunity for Domain Specific Treatments. Curr Neuropharmacol (2015) 0.79
Glia in the cytokine-mediated onset of depression: fine tuning the immune response. Front Cell Neurosci (2015) 0.79
Cytokines plasma levels during antidepressant treatment with sertraline and transcranial direct current stimulation (tDCS): results from a factorial, randomized, controlled trial. Psychopharmacology (Berl) (2013) 0.79
Is there Progress? An Overview of Selecting Biomarker Candidates for Major Depressive Disorder. Front Psychiatry (2016) 0.79
Norepinephrine-enhancing antidepressant exposure associated with reduced antiviral effect of interferon alpha on hepatitis C. Psychopharmacology (Berl) (2015) 0.79
Postsurgical Depressive Symptoms and Proinflammatory Cytokine Elevations in Women Undergoing Primary Treatment for Breast Cancer. Psychosom Med (2016) 0.78
Bipolar Disorder: Role of Inflammation and the Development of Disease Biomarkers. Psychiatry Investig (2015) 0.78
Neuroimmunomodulation in unipolar depression: a focus on chronobiology and chronotherapeutics. J Neural Transm (Vienna) (2012) 0.78
Antidepressant treatment response is modulated by genetic and environmental factors and their interactions. Ann Gen Psychiatry (2014) 0.78
The impact of treatment with selective serotonin reuptake inhibitors on primate cardiovascular disease, behavior, and neuroanatomy. Neurosci Biobehav Rev (2016) 0.78
Neutrophil-lymphocyte ratio in patients with major depressive disorder undergoing no pharmacological therapy. Neuropsychiatr Dis Treat (2015) 0.77
Chronic peripheral inflammation, hippocampal neurogenesis, and behavior. Brain Behav Immun (2016) 0.77
Prevention of unpredictable chronic stress-related phenomena in zebrafish exposed to bromazepam, fluoxetine and nortriptyline. Psychopharmacology (Berl) (2016) 0.77
Cellular and Molecular Inflammatory Profile of the Choroid Plexus in Depression and Suicide. Front Psychiatry (2015) 0.77
Antidepressant compounds can be both pro- and anti-inflammatory in human hippocampal cells. Int J Neuropsychopharmacol (2014) 0.77
Association between Interlukin-6 (IL-6), Interlukin-10 (IL-10) and depression in patients undergoing Hematopoietic stem cell transplantation. Int J Hematol Oncol Stem Cell Res (2015) 0.77
Lipopolysaccharide-Induced Behavioral Alterations Are Alleviated by Sodium Phenylbutyrate via Attenuation of Oxidative Stress and Neuroinflammatory Cascade. Inflammation (2016) 0.76
Antidepressants Impact Connexin 43 Channel Functions in Astrocytes. Front Cell Neurosci (2016) 0.76
IL-1β and BDNF are associated with improvement in hypersomnia but not insomnia following exercise in major depressive disorder. Transl Psychiatry (2015) 0.76
The fiery landscape of depression: A review of the inflammatory hypothesis. Pak J Med Sci (2013) 0.76
Salivary and serum biomarkers for the study of side effects of aripiprazole coprescribed with mirtazapine in rats. Int J Clin Exp Med (2015) 0.76
Sertraline reduces IL-1β and TNF-α mRNA expression and overcomes their rise induced by seizures in the rat hippocampus. PLoS One (2014) 0.76
Stress-Related Immune Markers in Depression: Implications for Treatment. Int J Neuropsychopharmacol (2016) 0.76
Electroconvulsive seizures (ECS) do not prevent LPS-induced behavioral alterations and microglial activation. J Neuroinflammation (2015) 0.75
Influence of fluvoxamine on plasma interleukin-6 or clinical improvement in patients with major depressive disorder. Neuropsychiatr Dis Treat (2017) 0.75
Mitigation of Inflammation-Induced Mood Dysregulation by Long-Chain Omega-3 Fatty Acids. J Am Coll Nutr (2015) 0.75
Role of Sirtuins in Linking Metabolic Syndrome with Depression. Front Cell Neurosci (2016) 0.75
Levels of serum immunomodulators and alterations with electroconvulsive therapy in treatment-resistant major depression. Neuropsychiatr Dis Treat (2016) 0.75
The role of interleukin genes in the course of depression. Open Med (Wars) (2016) 0.75
Posttraumatic Stress Disorder: Does the Gut Microbiome Hold the Key? Can J Psychiatry (2016) 0.75
Mirtazapine treatment of a severe depressive episode and resolution of elevated inflammatory markers. Case Rep Psychiatry (2013) 0.75
Repeatedly administered antidepressant drugs modulate humoral and cellular immune response in mice through action on macrophages. Exp Biol Med (Maywood) (2016) 0.75
Neuroinflammation and cytokine abnormality in major depression: Cause or consequence in that illness? World J Psychiatry (2016) 0.75
Serum Cytokine Levels in Major Depressive Disorder and Its Role in Antidepressant Response. Psychiatry Investig (2016) 0.75
Hippocampal CysLT1R knockdown or blockade represses LPS-induced depressive behaviors and neuroinflammatory response in mice. Acta Pharmacol Sin (2017) 0.75
Cost-utility and biological underpinnings of Mindfulness-Based Stress Reduction (MBSR) versus a psychoeducational programme (FibroQoL) for fibromyalgia: a 12-month randomised controlled trial (EUDAIMON study). BMC Complement Altern Med (2016) 0.75
Behavioural Effects of Using Sulfasalazine to Inhibit Glutamate Released by Cancer Cells: A Novel target for Cancer-Induced Depression. Sci Rep (2017) 0.75
Inhibitors of Fatty Acid Amide Hydrolase and Monoacylglycerol Lipase: New Targets for Future Antidepressants. Curr Neuropharmacol (2015) 0.75
Inflammatory markers and chronic exposure to fluoxetine, divalproex, and placebo in intermittent explosive disorder. Psychiatry Res (2015) 0.75
Inflammation and Immune Regulation as Potential Drug Targets in Antidepressant Treatment. Curr Neuropharmacol (2016) 0.75
Shen-Qi-Jie-Yu-Fang exerts effects on a rat model of postpartum depression by regulating inflammatory cytokines and CD4(+)CD25(+) regulatory T cells. Neuropsychiatr Dis Treat (2016) 0.75
Reduced Venous Blood Basophil Count and Anxious Depression in Patients with Major Depressive Disorder. Psychiatry Investig (2016) 0.75
Diene Valepotriates from Valeriana glechomifolia Prevent Lipopolysaccharide-Induced Sickness and Depressive-Like Behavior in Mice. Evid Based Complement Alternat Med (2015) 0.75
Microglia: An Interface between the Loss of Neuroplasticity and Depression. Front Cell Neurosci (2017) 0.75
Altered soluble epoxide hydrolase-derived oxylipins in patients with seasonal major depression: An exploratory study. Psychiatry Res (2017) 0.75
The relationship between antidepressant treatment and inflammatory markers in early psychosis: preliminary results. Psychopharmacology (Berl) (2016) 0.75
Inflammation and its discontents: the role of cytokines in the pathophysiology of major depression. Biol Psychiatry (2009) 8.74
A meta-analysis of cytokines in major depression. Biol Psychiatry (2009) 7.16
Associations of depression with C-reactive protein, IL-1, and IL-6: a meta-analysis. Psychosom Med (2009) 7.06
Cytokine-associated emotional and cognitive disturbances in humans. Arch Gen Psychiatry (2001) 4.70
Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet (2006) 4.26
A mechanism converting psychosocial stress into mononuclear cell activation. Proc Natl Acad Sci U S A (2003) 3.82
Increased stress-induced inflammatory responses in male patients with major depression and increased early life stress. Am J Psychiatry (2006) 3.33
The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine. Mol Psychiatry (2006) 2.44
Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression. Cytokine (1997) 2.43
MicroRNA-132 potentiates cholinergic anti-inflammatory signaling by targeting acetylcholinesterase. Immunity (2009) 2.33
The cholinergic anti-inflammatory pathway. Brain Behav Immun (2005) 2.13
An fMRI study of cytokine-induced depressed mood and social pain: the role of sex differences. Neuroimage (2009) 1.79
Acute inflammation and negative mood: mediation by cytokine activation. Brain Behav Immun (2004) 1.73
Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression. J Affect Disord (1995) 1.65
IDO upregulates regulatory T cells via tryptophan catabolite and suppresses encephalitogenic T cell responses in experimental autoimmune encephalomyelitis. J Immunol (2010) 1.46
Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder. Psychopharmacology (Berl) (2003) 1.46
Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission. Eur Arch Psychiatry Clin Neurosci (1997) 1.41
Immunological effects of induced shame and guilt. Psychosom Med (2004) 1.40
Anti-inflammatory properties of desipramine and fluoxetine. Respir Res (2007) 1.38
Pro-inflammatory cytokines and treatment response to escitalopram in major depressive disorder. Prog Neuropsychopharmacol Biol Psychiatry (2007) 1.37
Inflammation, sanitation, and consternation: loss of contact with coevolved, tolerogenic microorganisms and the pathophysiology and treatment of major depression. Arch Gen Psychiatry (2010) 1.37
Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine. Ann N Y Acad Sci (1995) 1.36
Pro- and anti-inflammatory cytokine balance in major depression: effect of sertraline therapy. Clin Dev Immunol (2007) 1.34
Does cytokine-induced depression differ from idiopathic major depression in medically healthy individuals? J Affect Disord (2009) 1.28
A critical review of human endotoxin administration as an experimental paradigm of depression. Neurosci Biobehav Rev (2009) 1.24
IL-6 levels decrease with SSRI treatment in patients with major depression. Hum Psychopharmacol (2005) 1.20
Effects of antidepressant drugs on the behavioral and physiological responses to lipopolysaccharide (LPS) in rodents. Neuropsychopharmacology (2001) 1.19
Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis. Eur Neuropsychopharmacol (2001) 1.16
Imbalance between pro- and anti-inflammatory cytokines, and between Th1 and Th2 cytokines in depressed patients: the effect of electroacupuncture or fluoxetine treatment. Pharmacopsychiatry (2009) 1.16
Neuroimmune and cortisol changes in selective serotonin reuptake inhibitor and placebo treatment of chronic posttraumatic stress disorder. Biol Psychiatry (2004) 1.14
Body weight, the tumor necrosis factor system, and leptin production during treatment with mirtazapine or venlafaxine. Pharmacopsychiatry (2002) 1.10
Effects of selective serotonin reuptake inhibitor therapy on endothelial function and inflammatory markers in patients with coronary heart disease. Clin Pharmacol Ther (2009) 1.09
Low vagal tone is associated with impaired post stress recovery of cardiovascular, endocrine, and immune markers. Eur J Appl Physiol (2010) 1.05
Regulatory T cells increased while IL-1β decreased during antidepressant therapy. J Psychiatr Res (2010) 1.02
Neural aspects of immunomodulation: focus on the vagus nerve. Brain Behav Immun (2010) 1.02
Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan. Neuropsychobiology (2001) 1.01
Pro-inflammatory biomakers in depression: treatment with venlafaxine. World J Biol Psychiatry (2009) 1.00
Variations in circulating cytokine levels during 52 week course of treatment with SSRI for major depressive disorder. Eur Neuropsychopharmacol (2008) 1.00
Association between enhanced soluble CD40 ligand and proinflammatory and prothrombotic states in major depressive disorder: pilot observations on the effects of selective serotonin reuptake inhibitor therapy. J Clin Psychiatry (2006) 0.99
Plasma levels of interleukin-6, interleukin-10, and interleukin-1 receptor antagonist in depression: comparison between the acute state and after remission. Pol J Pharmacol (2001) 0.99
Higher plasma interleukin-6 (IL-6) level is associated with SSRI- or SNRI-refractory depression. Prog Neuropsychopharmacol Biol Psychiatry (2009) 0.99
Citalopram reduces endotoxin-induced fatigue. Brain Behav Immun (2010) 0.97
Infection, depression, and immunity in women after coronary artery bypass: a pilot study of cognitive behavioral therapy. Altern Ther Health Med (2007) 0.95
Effects of antidepressants on weight and on the plasma levels of leptin, TNF-alpha and soluble TNF receptors: A longitudinal study in patients treated with amitriptyline or paroxetine. Neuropsychopharmacology (2000) 0.94
Effects of eicosapentaenoic acid and fluoxetine on plasma cortisol, serum interleukin-1beta and interleukin-6 concentrations in patients with major depressive disorder. Psychiatry Res (2010) 0.94
The effects of antidepressant treatment on serum cytokines and nutritional status in hemodialysis patients. J Korean Med Sci (2004) 0.92
Successful antidepressant therapy restores the disturbed interplay between TNF-alpha system and HPA axis. Biol Psychiatry (2006) 0.92
Seven days' around the clock exhaustive physical exertion combined with energy depletion and sleep deprivation primes circulating leukocytes. Eur J Appl Physiol (2006) 0.89
Antidepressant effects on insulin sensitivity and proinflammatory cytokines in the depressed males. Mediators Inflamm (2010) 0.87
Effects of bupropion augmentation on pro-inflammatory cytokines in escitalopram-resistant patients with major depressive disorder. J Psychopharmacol (2008) 0.84
Increase in IL-6 levels among major depressive disorder patients after a 6-week treatment with duloxetine 60 mg/day: a preliminary observation. Neuropsychiatr Dis Treat (2011) 0.84
Effects of behavioral stimuli on plasma interleukin-1 activity in humans at rest. J Clin Psychol (1993) 0.78
Intact noradrenaline transporter is needed for the sympathetic fine-tuning of cytokine balance. Eur J Pharmacol (2003) 0.78
Proteomic analysis of tumor necrosis factor-alpha resistant human breast cancer cells reveals a MEK5/Erk5-mediated epithelial-mesenchymal transition phenotype. Breast Cancer Res (2008) 1.35
Riluzole in the treatment of mood and anxiety disorders. CNS Drugs (2008) 1.24
Expression patterns of potential therapeutic targets in prostate cancer. Int J Cancer (2005) 1.20
Predictors of angina pectoris versus myocardial infarction from the Women's Health Initiative Observational Study. Am J Cardiol (2004) 1.07
Citalopram reduces endotoxin-induced fatigue. Brain Behav Immun (2010) 0.97
The neuroinflammation marker translocator protein is not elevated in individuals with mild-to-moderate depression: a [¹¹C]PBR28 PET study. Brain Behav Immun (2013) 0.92
Clinical treatment of obsessive compulsive disorder. Psychiatry (Edgmont) (2005) 0.81
From too little too late to early and often: child psychiatry education during medical school (and before and after). Child Adolesc Psychiatr Clin N Am (2007) 0.80
Outcome of third renal allograft retransplants versus primary transplants from paired donors. Transplantation (2009) 0.80
Comparison of short- and long-term outcomes after early versus late liver retransplantation: a single-center experience. J Surg Res (2013) 0.77
Model curriculum for academic child and adolescent psychiatry training. Acad Psychiatry (2008) 0.75
The benefit of smart phone usage in liver organ procurement. J Telemed Telecare (2011) 0.75